Clinical applications of Gallium-68

Research output: Contribution to journalReview article

Abstract

Gallium-68 is a positron-emitting radioisotope that is produced from a 68Ge/68Ga generator. As such it is conveniently used, decoupling radiopharmacies from the need for a cyclotron on site. Gallium-68-labeled peptides have been recognized as a new class of radiopharmaceuticals showing fast target localization and blood clearance. 68Ga-DOTATOC, 8Ga-DOTATATE, 68Ga-DOTANOC, are the most prominent radiopharmaceuticals currently in use for imaging and differentiating lesions of various somatostatin receptor subtypes, overexpressed in many neuroendocrine tumors. There has been a tremendous increase in the number of clinical studies with 68Ga over the past few years around the world, including within the United States. An estimated ~10,000 scans are being performed yearly in Europe at about 100 centers utilizing 68Ga-labeled somatostatin analogs within clinical trials. Two academic sites within the US have also begun to undertake human studies. This review will focus on the clinical experience of selected, well-established and recently applied 68Ga-labeled imaging agents used in nuclear medicine.

Original languageEnglish (US)
Pages (from-to)2-13
Number of pages12
JournalApplied Radiation and Isotopes
Volume76
DOIs
StatePublished - Jun 1 2013

Keywords

  • Clinical trials
  • Neuroendocrine tumor
  • PET
  • Radiopeptides
  • Somatostatin receptor

ASJC Scopus subject areas

  • Radiation

Fingerprint Dive into the research topics of 'Clinical applications of Gallium-68'. Together they form a unique fingerprint.

  • Cite this